TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02733523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program Sentirnos bien (Feeling well)
Description: Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:~1. Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.~2. Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.~3. Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food.
Study: NCT04223713

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TriRec
Description: Trileaflet Reconstruction of the Aortic Valve

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement
Description: Biological Prosthesis, Device: Edwards Perimount
Study: NCT03676972

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LithoVue Ureteroscope System
Description: The LithoVue System is intended to be used to visualize organs, cavities and canals in the urinary tract (urethra, bladder, ureter, calyces and renal papillae) via transurethral or percutaneous access routes.
Study: NCT00458120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated 10\^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
Study: NCT00987506

Intervention type: DEVICE
Intervention: XIENCE V®
Description: Participants with placement of a XIENCE V® EESS
Study: NCT00458120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN1delta30
Description: Live attenuated 10\^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2/4delta30(ME)
Description: Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rDEN2/4delta30(ME)
Description: Live attenuated 10\^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to rDEN1delta30 or rDEN2/4delta30(ME)
Description: Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
Study: NCT02294058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Capsules for oral administration once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Capsules for oral administration once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta-1a
Description: Administered by intramuscular injection once a week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to ozanimod
Description: Matching placebo capsules administered orally once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to interferon beta-1a
Description: Placebo intramuscular injection once a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to interferon beta-1a
Description: Placebo intramuscular injection once a week
Study: NCT01950403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linaclotide acetate
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04635956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug therapy
Description: 6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab
Study: NCT01256229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cochlear implantation
Description: This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
Study: NCT01950403

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01256229

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cochlear implantation
Description: This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
Study: NCT04363879

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratch with Pipelle curette
Description: For patients in the Pipelle curette group, physicians inserted the Pipelle curette into the uterus and removed an adequate endometrial sample using vigorous motion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial scratch with Shepard catheter
Description: For patients in the Shepard catheter group, physicians performed a four-quadrant scratch technique by inserting the Shepard insemination catheter into the uterus at 12:00. The catheter was then turned one-quarter turn and withdrawn. This was repeated two more times so that four endometrial quadrants were touched by the catheter at 12:00, 3:00, 6:00, and 9:00.
Study: NCT01908452

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pyridoxine
Description: 1200 mg/d during 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Description: 1200 mg/d during 12 weeks
Study: NCT00700713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide diphtheria toxoid conjugate
Description: 0.5 mL, IM
Study: NCT03576378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BrentuximabVedotin (BV)
Description: All patients will be treated with 6 cycles of BV-EPEM
Study: NCT01745445

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concurrent chemo-radiotherapy arm
Description: VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
Study: NCT00748098

Intervention type: DRUG
Group type: OTHER
Intervention: GSK1838262 Extended Release Tablets
Description: GSK1838262 extended release tablets
Study: NCT04428151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 20 mg once daily, taken as oral capsules

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg 30-minute IV infusion on day 1 of each 21-day cycle
Study: NCT01256229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hearing aids
Description: This is the conventional therapy for deaf children with developmental delays.
Study: NCT04428151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m\^2 administered as an IV infusion on day 1 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1250 mg/m\^2 twice daily on days 1-14 of each 21-day cycle, taken as oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400 mg/m\^2 loading dose, followed by 250 mg/m\^2 administered as an IV infusion on days 1, 8, and 15 of each 21-day cycle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenvatinib
Description: 24 mg once daily, taken as oral capsules
Study: NCT03763019

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional rehabilitation
Description: Static and dynamic control of position, balance skills, weight shift, and activities of daily living.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Static and dynamic control of position, balance skills, weight shift, and activities of daily living.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory rehabilitation
Description: Forced expiration, forced inspiration (thoracal expansion exercise), coughing exercise, incentive spirometric trainer, diaphragmatic respiration exercise, autogenic drainage, percussion.
Study: NCT03407755

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraocular gas
Description: Participants randomized to either air or SF6 gas in the anterior chamber.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraocular gas
Description: Participants randomized to either air or SF6 gas in the anterior chamber.
Study: NCT04015206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Interpersonal Psychotherapy
Description: Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group Interpersonal Psychotherapy
Description: Group Interpersonal Psychotherapy added to usual treatment (Pharmacotherapy + clinical management)
Study: NCT03708978

Intervention type: DIAGNOSTIC_TEST
Intervention: mammography
Description: When a woman comes to the clinic to receive mammography. Then a radiologist will give a BI-RADS classification after reviewing the images. If a BI-RADS 4/5 is obtained, the woman will receive pathological biopsy to ensure there is a benign or malignant lesion. If a BI-RADS 3 is obtained, the woman will be followed up by a half-year interval until two year after the first mammography. At each follow up, she will receive mammography. If a BI-RADS 4/5 is obtained at follow up, she will receive pathological biopsy; if a BI-RADS 1/2/3 is obtained at follow up, she will be followed up by a half-year interval until two year. If a BI-RADS 1/2 is obtained at the first mammography, the woman will receive a second mammography after two year. During the study period, breast examination and results will be recorded for every subject. Radiologists will give the diagnosis with and without AI support.
Study: NCT02527590

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pneumatic stimulations(allodynic area)
Description: 2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pneumatic stimulations (healthy area)
Description: 2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pneumatic stimulations no auditory masking
Description: 2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no stimulation (control)
Description: no stimulation (control condition): air jet directed beside the hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no stimulation (control)
Description: no stimulation (control condition): air jet directed beside the hand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pneumatic stimulations with audidory masking
Description: 2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
Study: NCT02292719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBV/PTV/r
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Tablet
Study: NCT03081130

Intervention type: PROCEDURE
Intervention: Intravenous laser irradiation treatment
Description: control group
Study: NCT03078504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous renal replacement therapy using System One (TM) setup (Nxstage)
Description: Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
Study: NCT04171050

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anaesthetic
Description: Local anesthesia injections

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pudendal Nerve Block plus anesthesia
Description: Local anesthesia injections plus a pudendal nerve block
Study: NCT02842294

Intervention type: DRUG
Intervention: Bevacizumab

Intervention type: DRUG
Intervention: Bevacizumab

Intervention type: DRUG
Intervention: Bevacizumab
Study: NCT04651868

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: A 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-2
Description: A 210 mins intravenous infusion with GLP-2 (10 pmol × kg\^-1 × min\^-1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A 210 mins intravenous infusion with isotonic NaCl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A 210 mins intravenous infusion with isotonic NaCl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCK
Description: A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CCK
Description: A 180 mins intravenous infusion with cholecystokinin (0.4 pmol × kg\^-1 × min\^-1)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A 180 mins intravenous infusion with isotonic NaCl

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A 180 mins intravenous infusion with isotonic NaCl
Study: NCT04328740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TP-1454 monotherapy
Description: Flat dose once or twice daily, alone
Study: NCT00607087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin aspart
Description: 100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
Study: NCT01824550

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: home-based exercise training condition
Description: Home based endurance exercise training
Study: NCT00779493

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: curcumin
Description: curcumin 900mg twice daily by mouth

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule to simulate 900mg curcumin capsule
Study: NCT01648972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03612336

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.
Study: NCT00748098

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study: NCT00104858

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given PO
Study: NCT03148353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Subacromial injection
Description: 1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Subacromial injection
Description: 1. Modified ultrasound guided corticosteroid subacromial injection~2. Standardized ultrasound guided corticosteroid subacromial injection
Study: NCT04506034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patches
Description: for every port entry site from the three in ports of laparoscope, patients received three lidocaine patches 5% (Lidoderm® , Endo Pharmaceuticals, Chadds Ford, PA). Each patch measured 10 cm × 14 cm and contains (700 mg), was divided into two equal parts, six parts applied two of it around one port entry site that marked before sterilization and just before induction of anesthesia. The patches not changed until removed after return of bowel function or on the maximum at fifth postoperative day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV lidocaine
Description: received i.v. lidocaine infusion after induction of anesthesia, 2 mg/min if body weight \>70 kg or 1 mg/min if body weight \<70 kg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV saline infusion
Description: received i.v. saline infusion.
Study: NCT02845557

Intervention type: OTHER
Intervention: OGTT and IVGTT tests

Intervention type: OTHER
Intervention: OGTT and IVGTT tests
Study: NCT04869046

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Instillation of levobupivacaine in surgical wound
Description: Once the hernia tissue had been surgically managed, the wound was sutured in layers and a solution of 0.5% levobupivacaine, 0.5 mg/kg (0.1 ml/kg), was instilled into the wound of children in the experimental group before suturing of the abdominal fascia. That same amount of 0.9% saline was given to children in the control group. The absorption of the solution took approximately 3 minutes, after which the wound was sutured. After completion of wound suturing, all children received 20 mg/kg of paracetamol administered as a rectal suppository.
Study: NCT05581459

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 63 Hz Vibration
Description: Vibrations of 63 Hz were applied with handheld vibration device.
Study: NCT00104858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT05581459

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 42 Hz Vibration
Description: Vibrations of 42 Hz were applied with handheld vibration device.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham vibration
Description: Handheld device was applied to the participants without any vibrations.
Study: NCT00104858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo HSCT